142 related articles for article (PubMed ID: 31356816)
1. Bromodomain-containing protein 4 contributes to renal fibrosis through the induction of epithelial-mesenchymal transition.
Wang X; Zhou Y; Peng Y; Huang T; Xia F; Yang T; Duan Q; Zhang W
Exp Cell Res; 2019 Oct; 383(2):111507. PubMed ID: 31356816
[TBL] [Abstract][Full Text] [Related]
2. BRD4 is a novel therapeutic target for liver fibrosis.
Ding N; Hah N; Yu RT; Sherman MH; Benner C; Leblanc M; He M; Liddle C; Downes M; Evans RM
Proc Natl Acad Sci U S A; 2015 Dec; 112(51):15713-8. PubMed ID: 26644586
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage.
Suarez-Alvarez B; Morgado-Pascual JL; Rayego-Mateos S; Rodriguez RM; Rodrigues-Diez R; Cannata-Ortiz P; Sanz AB; Egido J; Tharaux PL; Ortiz A; Lopez-Larrea C; Ruiz-Ortega M
J Am Soc Nephrol; 2017 Feb; 28(2):504-519. PubMed ID: 27436852
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoproteomics reveal novel protective activity of bromodomain containing 4 inhibitors on vascular homeostasis in TLR3-mediated airway remodeling.
Zhao Y; Tian B; Sun H; Zhang J; Zhang Y; Ivannikov M; Motamedi M; Liu Z; Zhou J; Kaphalia L; Calhoun WJ; Maroto R; Brasier AR
J Proteomics; 2019 Aug; 205():103415. PubMed ID: 31195152
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Targeting of BET Bromodomains Inhibits Lens Fibrosis via Downregulation of MYC Expression.
Wang X; Wang B; Zhao N; Wang C; Huang M; Chen B; Chen J; Sun Y; Xiong L; Huang S; Liu Y
Invest Ophthalmol Vis Sci; 2019 Nov; 60(14):4748-4758. PubMed ID: 31731295
[TBL] [Abstract][Full Text] [Related]
6. BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury.
Saiz ML; Lozano-Chamizo L; Florez AB; Marciello M; Diaz-Bulnes P; Corte-Iglesias V; Bernet CR; Rodrigues-Diez RR; Martin-Martin C; Rodriguez-Santamaria M; Fernandez-Vega I; Rodriguez RM; Diaz-Corte C; Suarez-Alvarez B; Filice M; Lopez-Larrea C
Biomed Pharmacother; 2024 May; 174():116492. PubMed ID: 38537579
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of BET protein BRD4 delays murine lupus.
Wei S; Sun Y; Sha H
Int Immunopharmacol; 2015 Dec; 29(2):314-319. PubMed ID: 26590112
[TBL] [Abstract][Full Text] [Related]
8. Attenuating Effects of Dieckol on Hypertensive Nephropathy in Spontaneously Hypertensive Rats.
Son M; Oh S; Choi J; Jang JT; Son KH; Byun K
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921823
[TBL] [Abstract][Full Text] [Related]
9. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
[TBL] [Abstract][Full Text] [Related]
10. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells.
Sui S; Zhang J; Xu S; Wang Q; Wang P; Pang D
Cell Death Dis; 2019 Apr; 10(5):331. PubMed ID: 30988278
[TBL] [Abstract][Full Text] [Related]
11. BRD4 suppression alleviates cerebral ischemia-induced brain injury by blocking glial activation via the inhibition of inflammatory response and pyroptosis.
Zhou Y; Gu Y; Liu J
Biochem Biophys Res Commun; 2019 Nov; 519(3):481-488. PubMed ID: 31530390
[TBL] [Abstract][Full Text] [Related]
12. Circulating miR-103a-3p contributes to angiotensin II-induced renal inflammation and fibrosis via a SNRK/NF-κB/p65 regulatory axis.
Lu Q; Ma Z; Ding Y; Bedarida T; Chen L; Xie Z; Song P; Zou MH
Nat Commun; 2019 May; 10(1):2145. PubMed ID: 31086184
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis.
Xiong C; Masucci MV; Zhou X; Liu N; Zang X; Tolbert E; Zhao TC; Zhuang S
Oncotarget; 2016 Oct; 7(43):69291-69308. PubMed ID: 27732564
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Novel Highly Specific Bromodomain-Containing Protein 4 Inhibitors in Innate Inflammation-Driven Airway Remodeling.
Tian B; Liu Z; Litvinov J; Maroto R; Jamaluddin M; Rytting E; Patrikeev I; Ochoa L; Vargas G; Motamedi M; Ameredes BT; Zhou J; Brasier AR
Am J Respir Cell Mol Biol; 2019 Jan; 60(1):68-83. PubMed ID: 30153047
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of STAT3 activation mediated by toll-like receptor 4 attenuates angiotensin II-induced renal fibrosis and dysfunction.
Xu Z; Zou C; Yu W; Xu S; Huang L; Khan Z; Wang J; Liang G; Wang Y
Br J Pharmacol; 2019 Jul; 176(14):2627-2641. PubMed ID: 30958891
[TBL] [Abstract][Full Text] [Related]
16. SIRT3-KLF15 signaling ameliorates kidney injury induced by hypertension.
Li N; Zhang J; Yan X; Zhang C; Liu H; Shan X; Li J; Yang Y; Huang C; Zhang P; Zhang Y; Bu P
Oncotarget; 2017 Jun; 8(24):39592-39604. PubMed ID: 28465484
[TBL] [Abstract][Full Text] [Related]
17. Chrysin inhibits diabetic renal tubulointerstitial fibrosis through blocking epithelial to mesenchymal transition.
Kang MK; Park SH; Choi YJ; Shin D; Kang YH
J Mol Med (Berl); 2015 Jul; 93(7):759-72. PubMed ID: 26062793
[TBL] [Abstract][Full Text] [Related]
18. The Key Role of Epithelial to Mesenchymal Transition (EMT) in Hypertensive Kidney Disease.
Seccia TM; Caroccia B; Piazza M; Rossi GP
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330886
[TBL] [Abstract][Full Text] [Related]
19. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.
Joshi S; Singh AR; Liu KX; Pham TV; Zulcic M; Skola D; Chun HB; Glass CK; Morales GA; Garlich JR; Durden DL
Mol Cancer Ther; 2019 Jun; 18(6):1036-1044. PubMed ID: 31018997
[TBL] [Abstract][Full Text] [Related]
20. BRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma.
Wang L; Wu X; Wang R; Yang C; Li Z; Wang C; Zhang F; Yang P
Biol Res; 2017 May; 50(1):19. PubMed ID: 28545522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
